GSK To Launch Late-stage Testing Of Syncytial Virus Vaccine

GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by midstage trial results.

from Top Business News- News18.com https://ift.tt/3m6GY9z

• Tweet
• Share
• Share
• Share
• Share